NewsRx

Search our medical news database

Therapy

LY300046-HCI Potential New AIDS Treatment

Published in AIDS Weekly, July 24th, 1995

The nonnucleoside inhibitor LY300046-HCI is a potent inhibitor of HIV-1 reverse transcriptase and may be therapeutically significant in the treatment of AIDS.

It has recently been reported that nonnucleoside inhibitors of HIV-1 reverse transcriptase (RT) may be useful in AIDS chemotherapy. These derivatives exhibit high selectivity for HIV-1 RT but do not inhibit HIV-2 or any other nucleic acid polymerase. A number of such agents are being investigated in clinical trials, including tetrahydroimidazobenzodiazepinthiones (TIPO), dipyridodiazepinones, pyridinones, bisheteroarylpiperazines and (alpha)-anilidophenylacetamides.

An effort was made to...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook